Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

Shares of Moderna (MRNA) have rallied 202% since Aug. 18, fueled by positive news about the biotech company's experimental ...

That could leave the stock due for a pullback according to Citi, whose Street-low target of $80 would suggest a nearly 60% ...

Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. MRNA, Vaxcyte Inc. PCVX and Novavax Inc. NVAX are moving in the after-hours session on Monday. Moderna rose 0.17% to $203.56 after the ...

Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund falling 1.89% ...

Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.

Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares ...

Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be. That approach just cleared its ...

Sellas Life Sciences (SLS) and ImmunityBio (IBRX) drew fresh retail attention on Friday as Moderna's upcoming Nasdaq-100 ...

Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at ...

Moderna (MRNA) stock rose after confirming Nasdaq-100 inclusion, even as Citi downgrades the stock on valuation concerns.